A Phase I Study of Single and Multiple Doses of TAS-205 in Patients With Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2015
Price : $35 *
At a glance
- Drugs TAS 205 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 24 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 15 Oct 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.